

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 16, 2022

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-39138
(Commission File Number)

84-2984849
(IRS Employer
Identification No.)

2200 Bridge Pkwy Suite #102
Redwood City, California 94065
(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400
Registrant's telephone number, including area code

N/A
(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)	(Trading Symbol)	(Name of exchange on which registered)
Voting Common Stock, par value \$0.0001 per share	JSPR	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of \$11.50	JSPRW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On March 16, 2022, Jasper Therapeutics, Inc. (the “Company”) made available a corporate presentation (the “Presentation”). Representatives of the Company intend to use the Presentation in industry conferences, investor conferences and investor meetings from time to time.

The information in this Item 7.01, including the Presentation attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Jasper Therapeutics, Inc. Investor Presentation
104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JASPER THERAPEUTICS, INC.

Date: March 16, 2022

By: /s/ Jeet Mahal
Jeet Mahal
Chief Financial Officer, Chief Business Officer and Corporate
Secretary



Transforming the Field of Hematopoietic Stem Cell Therapies

Nasdaq: JSPR

March 2022

Safe Harbor Statement

Forward-Looking Statements

This investor presentation and any accompanying oral presentation (together, this "Presentation") contain forward-looking statements. All statements other than statements of historical fact contained in this Presentation, including statements regarding the future opportunities and prospects of Jasper Therapeutics, Inc. (together with its subsidiary, "Jasper" or the "Company"), including milestones, business strategy, and plans and objectives for future operations, are forward-looking statements. Jasper has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the "Risk Factors" section of the Company's Registration Statement on Form S-4 declared effective by the U.S. Securities and Exchange Commission (the "SEC") on August 26, 2021, and any Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or may subsequently file with the SEC. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely *from* those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Jasper undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Jasper's expectations.

Industry and Market Data

Certain data in this Presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties and is subject to change based on various factors.

Trademarks

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.



Jasper Highlights



- Science targeting the central role of stem cells to cure a growing number of fatal diseases



- **JSP191:** First in class Phase 1/2 anti-CD117 antibody conditioning agent
- Clinical data in SCID & AML/ MDS transplant populations, Potential Q1 2023 AML/ MDS pivotal FPI
- New therapeutic approach for disease modification in lower risk MDS patients to initiate in 2022



- **Jasper mRNA stem cells:** Novel hematopoietic stem cell mRNA platform to expand the curative potential of allogeneic and autologous cellular therapy
- In vivo POC in 2022, potential IND in 2023



- Team with expertise in hematopoietic stem cell transplant and track record in drug development




- Validating corporate and academic partnerships
- Cash runway through AML / MDS pivotal study start

JSP191 stem cell conditioning for AML/ MDS and SCID transplant patients

Two ongoing clinical trials with near term initiation of AML / MDS pivotal study

JSP191

Blocks SCF Binding to CD117



JSP191 blocks CD117 (Stem Cell Factor Receptor) leading to hematopoietic stem and progenitor cell depletion

- Synergistic with other stem cell targeting mechanisms (radiation¹, 5-azacytidine²)

JSP191 designed to minimize off target / safety effects

- Designed to remove effector cell recruitment and mast cell activation
- CD117 also expressed on mast cells, germ cells, Cajal (GI) cells, melanocytes

Clinical proof of concept established in two transplant studies with no JSP191 related SAEs to date

SCID:


- Single agent activity leading to successful donor engraftment and immune reconstitution

AML/ MDS:

- 17 of 17 patients with successful primary donor engraftment
- 12 of 15 with clearance of measurable residual disease
- Potential pivotal trial start by Q1 2023


New therapeutic approach for disease modification in lower risk MDS patients

JSP191 targets diseased MDS to potentially restore normal hematopoiesis



Time after JSP191 administration

JSP191 depletes diseased MDS cells in a mouse xenograft model¹



AML/MDS subjects receiving JSP191 0.6 mg/kg

New clinical data: Single dose of JSP191 alone directly depletes stem & progenitor cells²


Proof of concept study in lower risk MDS patients to be initiated in 2022



[1] Pang WW, Czechowicz A, Logan AG, et al. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. *Blood*. 2019;133(19):2069-2078. [2] Jasper Internal Data

Jasper mRNA technology for transient modification of gene therapy and stem cell grafts

Increasing stem cell proliferation, homing and modifying immune profile



- **Increased engraftment** of gene therapy & donor stem cell grafts
- **Reduced risk of graft vs. host disease**
- **Increased safety and utility** of cord blood & haploidentical transplant
- **Single product** applicable to multiple diseases

Jasper's Expanding Pipeline

Indication	R&D Partner	Research	Preclinical	Clinical	Milestones
JSP191 Conditioning					
Sponsored Studies					
AML/MDS					<ul style="list-style-type: none"> Updated Phase Ib data (TCT Meeting on April 26th) Pivotal trial initiation by Q1 2023
SCID					
Gene Therapy – Sickle Cell					2H 2022 first patient enrollment
Gene Therapy – Gaucher Type 1					2H 2022 first patient enrollment
Gene Therapy – X-SCID					2H 2022 first collaboration data
Investigator Sponsored Studies					
Fanconi Anemia					2022 patient enrollment ongoing
Sickle Cell Disease					2022 patient enrollment
Chronic Granulomatous Disease					2022 patient enrollment
GATA2 MDS					2022 patient enrollment
JSP191 Therapeutic					
Lower Risk MDS (primary treatment)					2H 2022 clinical study initiation
Jasper eHSC Platform					
Thalassemias, Sickle Cell Disease					<ul style="list-style-type: none"> 2022 – In vivo proof of concept 2023 – First IND filing
Autoimmune Diseases					



Jasper maintains full worldwide rights to develop and commercialize JSP191 and eHSCs in all indications

JSP191 is an investigational drug and is not approved for any indication 7



Transforming the Field of Hematopoietic Stem Cell Therapies

Nasdaq: JSPR

March 2022
